Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene (Nasdaq: EVGN) outlined a 2025 strategic transformation to focus on its proprietary ChemPass AI™ engine and two markets: human health and agriculture. The company divested non-core assets, resized the organization, and said ChemPass AI™ leverages a 38‑billion‑molecule foundation model and partnerships including Google Cloud, Bayer, and Corteva.
Evogene reported partnered drug discovery progress, four disclosed collaborations, AgPlenus agricultural programs, and completed divestments of Lavie Bio and a license of Biomica's BMC128.
Evogene (NASDAQ: EVGN) will release its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will discuss results in a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time).
Investors must register in advance to attend and the full webcast will be posted on the company's website a few days after the call. Registration link: https://www.veidan-conferencing.com/evogene.
Evogene (Nasdaq: EVGN) announced a collaboration with Dr. Mark Adams' group at Queensland University of Technology on Feb 17, 2026 to accelerate AI-driven discovery of small-molecule inhibitors targeting a newly identified enzymatic detoxification pathway that drives Cisplatin resistance in non-small cell lung cancer (NSCLC).
The partnership combines Evogene's ChemPass AI™ generative design platform with QUT's biological insights to generate and iteratively refine drug-like leads aimed at restoring chemotherapy and targeted-therapy sensitivity.
Evogene (Nasdaq: EVGN), Systasy Bioscience and LMU University Hospital Munich announced a collaborative program on Feb. 11, 2026 to develop novel therapies for neutrophil-driven hyper-inflammatory diseases, including IBD. The effort is supported by a pan-European EUREKA grant and includes participation from the Weizmann Institute.
Evogene will lead small-molecule discovery using its ChemPass AI™; Systasy will apply its PathwayProfiler DNA barcoding assays; LMU will validate leads in human stem cell–derived neutrophil models and advance biomarkers and translational plans.
Evogene (Nasdaq: EVGN) entered a warrant inducement agreement with an existing institutional investor to generate approximately $3.4 million of gross proceeds. The investor will immediately exercise August 2024 Series A and B warrants at $1.00 per share.
In return, the investor receives privately placed Series A-1 and B-1 warrants to buy up to 2,538,462 shares each at an exercise price of $1.25; A-1 expires in five years and B-1 in 18 months. Closing is expected on or about February 11, 2026, subject to customary conditions.
Evogene (NASDAQ: EVGN) announced on February 10, 2026 an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform using Google Cloud Vertex AI. The phase aims to accelerate and scale small-molecule discovery, shorten design–make–test–analyze cycles, and enable parallel molecular exploration.
The move follows a prior October 2024 milestone that built a generative AI foundation model now core to ChemPass AI™. Evogene said the partnership could broaden offerings, improve speed and cost structure, and make some tools available via Google Cloud Marketplace.
Evogene (NASDAQ: EVGN) appointed Prof. John J. Irwin (UCSF) and Prof. Dan T. Major (Bar-Ilan) to its Scientific Advisory Board on February 9, 2026.
The appointments are intended to strengthen scientific leadership for ChemPass AI™, Evogene's proprietary generative AI engine for small-molecule discovery across pharmaceutical and ag-chemical programs.
Evogene (NASDAQ: EVGN) subsidiary Biomica granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license to BMC128 (LS-LBP-002), a live four-strain microbiome-based therapeutic showing early Phase 1 clinical promise in renal cell carcinoma and non-small cell lung cancer.
BMC128 displayed an excellent safety profile and early signs of efficacy, including disease stabilization in patients with prior progression. Under the deal, Lishan Biotech will lead global development, manufacturing, and commercialization; Biomica is eligible for development milestones and future royalties. Lishan plans Phase 2 studies and regulatory filings in China and the United States.
Evogene (NASDAQ: EVGN) and Unravel Biosciences announced a collaboration on January 7, 2026 to discover and optimize a first-in-class small-molecule therapy aimed at restoring myelin and reversing neurological damage in demyelinating disorders including multiple sclerosis.
The program combines Evogene's ChemPass AI generative chemistry platform with Unravel's BioNAV predictive biology and Living Molecular Twins patient-derived data to design brain-penetrant inhibitors against a novel demyelination target discovered by Unravel. Work will use in vitro, in vivo, and in silico outcome simulation to advance lead candidates toward potential clinical development.
Evogene (Nasdaq: EVGN) appointed Dr. Olga Nissan as Vice President of Business Development, effective January 1, 2026. Dr. Nissan brings more than 15 years of experience across biotechnology, pharmaceutical and AI-enabled drug discovery and holds a PhD plus postdoctoral research in biochemistry and proteomics from the Weizmann Institute of Science.
Her prior roles include CEO and Co‑Founder of Protica Bio and senior R&D and management positions at EcoPhage, BiomX and Teva. Management says she will help scale Evogene's small‑molecule discovery and optimization powered by the ChemPass AI platform and expand industry collaborations.